Ontology highlight
ABSTRACT:
SUBMITTER: Bewersdorf JP
PROVIDER: S-EPMC9957935 | biostudies-literature | 2023 Feb
REPOSITORIES: biostudies-literature
Bewersdorf Jan Philipp JP Patel Kishan K KK Goshua George G Shallis Rory M RM Podoltsev Nikolai A NA Stahl Maximilian M Stein Eytan M EM Huntington Scott F SF Zeidan Amer M AM
Leukemia & lymphoma 20221209 2
Ivosidenib + azacitidine (IVO/AZA) is approved in the United States for newly diagnosed, older or intensive chemotherapy-ineligible patients with <i>IDH1</i>-mutated acute myeloid leukemia. We created a partitioned survival analysis model to evaluate the health economic implications of this approval. Model outputs were used to calculate the incremental cost-effectiveness ratio (ICER) of IVO/AZA versus AZA. One-way and probabilistic sensitivity analyses were conducted. In the base case scenario, ...[more]